Pay in 4 interest-free payments of $6.53 Learn more
Ships within 48 hours · Estimated delivery Nov 2 - Nov 7
Sumithran P, Prendergast LA, Delbridge E, et al
In a randomized, single-blind, 24-week study, participants assigned to dual therapy of 2 mg weekly of the GLP-1 receptor agonist exenatide (Bydureon, AstraZeneca) and 10 mg daily of the SGLT2 inhibitor dapagliflozin (Farxiga, AstraZeneca) lost more weight than those taking either agent alone or those receiving dapagliflozin and metformin extended-release (Xigduo XL, AstraZeneca) or phentermine/topiramate extended-release (Qsymia, Vivus)
There is no medical contraindication to starting GLP-1 therapy on any particular day
Losing this status meant less automatic reimbursement and fiercer price competition with Novo Nordisks weight loss drug
They can change the dose or how often you get shots based on your progress
